Edelweiss Financial Services Ltd, ICICI Securities Limited, SBI Capital Markets Limited
Tarsons Products Ltd. (TPL) is an Indian labware company engaged in the designing, development, manufacturing and marketing of ‘consumables’, ‘reusables’ and ‘others’ including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, Contract Research Organizations (“CROs”), Diagnostic companies and hospitals (Source: Frost & Sullivan Report). It manufactures a range of quality labware products that helps advance scientific discovery and improve healthcare (Source: Frost & Sullivan Report). As of March 31, 2021, the company has a diversified product portfolio with over 1,700 SKUs across 300 products. TPL caters to a diverse range of end customers across various sectors which include research organizations, academic institutions, pharmaceutical companies, CROs, diagnostic companies, and hospitals. Some of its end customers include customers such as Indian Institute of Chemical Technology, National Centre for Biological Sciences across academic institutes and research organizations; Dr Reddy’s Laboratories, Enzene Biosciences across pharmaceutical sectors; Syngene International, Veeda Clinical Research across CROs; and Molbio Diagnostics, Agappe Diagnostic, Metropolis Healthcare, Dr Lal Path Labs, Mylab Life Solutions across other sectors such as diagnostics. Trason’s products are used in various laboratories across research organizations, academic institutes, pharmaceutical companies, Contract Research Organizations (CRO), diagnostic companies, and hospitals. The company has many reputed institutes, medical labs, and hospitals as its key clients. Currently, the company has 5 manufacturing facilities located in West Bengal spread across approximately 20,000 sq. mts of area. The company has a strong distribution network across India comprising of over 141 authorized distributors as of March 31, 2021 and supplies its products to more than 40 countries.
For year/ period ended ( in Cr.)
|31 Mar 2021||31 Mar 2020||31 Mar 2019|
|Profit After Tax||68.87||40.53||38.95|
Tarsons Products Limited is the second-largest player in plastic labware and post-pandemic, due to rising concerns for health, this company is poised for bright prospects ahead. The issue appears reasonably priced based on its financial data and future prospects. TPL is enhancing its role and expanding its product portfolio. The scrip is expected to generate first-mover fancy post listing, Investors may consider investment for the medium to long term rewards.
Never Miss IPO Investment